SG1002 Inhibits Heart Remodeling Changes in a Hyperhomocysteinemia Cardiac Mouse Model
May 24, 2019
Paras K. Mishra et al. published in the journal of Frontiers in Physiology an article titled "Hydrogen Sulfide Ameliorates Homocysteine-Induced Cardiac Remodeling and Dysfunction" where it is demonstrated the in vivo cardioprotective effects of SG1002 in mice. GS1002 mitigates homocysteine-induced hypertrophy in cardiomyocytes and this stydy reveals that SG1002 reduces c-Jun and c-Fos expression, decreases interstitial fibrosis, and reduces cellular hypertrophy. Overall, SG1002 inhibited heart remodeling changes in a hyperhomocysteinemia cardiac mouse model.
Sulfagenix Inc. Granted New Patent in Europe for SG1002
April 24, 2019
The European Patent Office grants Sulfagenix Inc. Patent No. EP2756757 as published in European Patent Bulletin 19/17 on April 24, 2019.
SG1002 Positive Results in the Restoration of Contractile Protein Expression and Colonic Smooth Muscle in Duchenne Muscular Dystrophy Mice
April 1, 2019
Kulpreet Singh et al. publish in The FASEB Journal (vol. 33, in press) a paper titled "Restoration of Contractile Protein Expression and Colonic Smooth Muscle Function by H2S in Duchenne Muscular Dystrophy Mice" presenting results showing that acetylcholine-induced contractions in mice were decreased and partly reversed by SG1002 treatment. Similarly, expression of contractile proteins was also decreased and reversed by SG1002. The results support the therapeutic potential of SG1002 for the control of DMD-induced gastrointestinal motility disorders.
SG1002 Improves Aberrant Gastric Smooth Muscle Function in Duchenne Muscular Dystrophy Mice
April 1, 2019
Gurpreet Randhawa et al. publish in The FASEB Journal (vol. 33, in press) a paper titled " Hydrogen Sulfide Improves Aberrant Gastric Smooth Muscle Function in Duchenne Muscular Dystrophy Mice" presenting results showing that orally active and slow H2S-releasing SG1002 restores gastric smooth muscle function and contractile protein expression suggesting a therapeutic potential for SG1002 to treat motility disorders in Duchenne Muscular Dystrophy (DMD).
SG1002 For Prevention and Treatment of Duchenne Cardiomyopathy
April 1, 2019
Chad Cain et al. publish in The FASEB Journal (vol. 33, in press) a paper titled "Prevention and Treatment of Duchenne Cardiomyopathy with Hydrogen Sulfide-Donor Therapy" preseting results using SG1002 where in a ‘humanized’ mouse model of Duchenne muscular dystrophy (DMD) early treatment with SG1002 preserved cardiac function (ejection fraction; EF) throughout study duration and strongly support a daily H2S therapy for preservation of cardiac function, attenuation of skeletal muscle fibrosis and cardiac NLRP3 expression.
SG1002 in editorial of Nature Medicine
January 14, 2019
After interviewing Drs. Ingrid Fleming (corresponding author of the Jan 2 CIRCULATION paper), Suowen Xu (a pharmacology researcher at the University of Rochester), Matthias Barton (the cardiologist at the University of Zurich who co-authored the above-mentioned editorial piece) and Professor Dr. John L Wallace (the physiologist/pharmacologist/entrepreneur based at the University of Calgary who founded a company that develops hydrogen -sulfide-releasing anti-inflammatory drugs), science writer Colin Barras wrote a piece titled SMELLY GAS PROTECTS AGAINST CLOGGED ARTERIES and posted it on NATURE’S WEBSITE. In this news item, Ingrid Fleming is quoted as stating that THE EFFECT (of SG1002) EXCEEDED OUR EXPECTATIONS, and that SG1002 MAY HAVE THE POTENTIAL TO HELP PEOPLE WITH ATHEROSCLEROSIS, while Dr Barton said he was PARTICULARLY IMPRESSED BY THE FACT THAT THE RESEARCHERS STUDIED BOTH MOUSE AND HUMAN TISSUES.
SG1002 as a therapeutic approach for atherosclerosis
January 2, 2019
A research article in the journal CIRCULATION (vol. 139:101-114) informs the excellent results obtained upon SG1002 treatment of atherosclerosis in a murine model. The researchers point out that “oral supplementation with hydrogen sulfide donors (e.g., SG1002) may serve as a therapeutic approach to attenuate atherosclerosis development in humans”. The authors also conclude that “ provided that this drug( SG1002 ) is proven to be safe, clinical testing in patients with coronary atherosclerosis may be warranted.”
April 24, 2015
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise through the assistance of Australia’s R&D tax incentive.
May 14, 2014
Interview with Tony Giordano, PhD, CEO of Sulfagenix, Inc. recorded by TiETV Lite at the TiEcon 2014 Media Lounge.
by Lynn Fosse, Senior Editor, CEOCFO Magazine, July 7, 2014
Sulfagenix, Inc., and its wholly owned subsidiary, Sulfagenix Australia Pty. Ltd, is built on decades of research on modifying existing molecules to improve safety, bioavailability and efficacy for new uses.
Cleveland biotechnology company Sulfagenix has secured a key patent related to its efforts to develop hydrogen sulfide prodrugs (inactive drug precursors converted into active form in the body by normal metabolic processes).
January 29, 2013
Sulfagenix, Inc. is pleased to announce the issuance of a key patent related to its efforts to develop hydrogen sulfide prodrugs.
by Deanna Pogorelc, January 30, 2013
MedCity News reported on Sulfagenix’s lead compound SG1002 and its efforts to develop hydrogen sulfide prodrugs.
by Jane E. Allen, November 16, 2011
ABC News reported on the potential of hydrogen sulfide-releasing drugs, like Suflagenix’s NP-1002, for treating cardiovascular disease.
by Stephanie Seneff, Ph.D., July 2, 2011
The Weston A. Price Foundation posted this article on the detrimental effects of sulfur deficiency.
by Mitch Leslie, May 30, 2008